Articles tagged with Metastasis
FAU researchers identified Zeb1 as a key factor that activates embryonic programme, leading to rapid dissemination and metastasis in pancreatic cancer. They also found that blocking Zeb1 reduces metastatic capacity in other tumour types.
A large study found patients with follicular and medullary thyroid cancer had the highest rate of bone lesions and fractures, and increased risk of death. Researchers suggest targeting this high-risk population with specific drugs to prevent or treat complications.
Researchers developed a method to isolate EVs from blood samples, enabling rapid analysis and potential personalized anticancer treatments. The technique uses nanoprobes to capture EVs within 15 minutes, offering an alternative to invasive methods.
Scientists have discovered that cancer can commandeers immature immune cells, called MDSCs, to facilitate its spread. MDSCs are normally part of the immune system's anti-tumor response but, under the influence of tumor-secreted cytokines, they can help tumors grow and metastasize.
Scientists have identified a biomarker, SMARCE1, that distinguishes poorly invasive tumors from those likely to spread and metastasize in early-stage breast cancer. This discovery enables doctors to tailor therapies designed to match the behavior of each patient's cancer, improving treatment outcomes.
A University of Colorado Cancer Center study found that knocking down the Jumonji protein KDM3A inhibits Ewing's Sarcoma metastasis. The researchers also discovered another protein, Melanoma Cell Adhesion Molecule (MCAM), plays a crucial role in the cancer's spread.
Researchers have identified pre-metastatic niches that prepare the ground for tumor cells to survive before invading other organs. Understanding this phenomenon could lead to new diagnostic and therapeutic tools to prevent cancer-related death.
Researchers at JAX have received $2.8 million in federal grants to develop better diagnostics and treatments for triple-negative breast cancer (TNBC). The studies aim to understand the underlying mechanisms that control metastasis and identify promising therapeutic targets.
Researchers found that breast cancer cells express reelin, a protein typically found in the brain, to disguise themselves and avoid detection. This allows them to form new deadly brain tumors, leading to high mortality rates among women with HER2-positive breast cancer.
Research at the University of Illinois Chicago found that blocking a protein on ovarian cancer cells can prevent its spread to other organs. The study's lead researcher believes this discovery could be a key to developing new treatments for the disease.
A recent study published in the American Journal of Roentgenology found that FDG PET/CT is a valuable imaging tool for treating lung cancer patients, especially when clinical suspicion or evidence of disease recurrence or metastasis is present. However, its routine use without clinical suspicion should be discouraged until its value fo...
Researchers discovered that weakly adherent cancer cells are more likely to migrate and invade other tissues compared to strongly adherent cells. This finding suggests that adhesion strength may serve as a general marker of metastatic cells.
Researchers found that cancer cells can spread through the extracellular matrix with optimal tissue stiffness. Drugs targeting ECM stiffness could prevent metastasis, providing a new approach to diagnostics and treatment.
A new study from Michigan Medicine identifies a protein in the microenvironment of metastatic breast cancer cells that promotes their spread. The researchers found that this protein, DDR2, plays a key role in fueling the growth and migration of cancer cells, and that inhibiting it may prevent metastasis.
Researchers compared stereotactic radiosurgery to whole-brain radiation for metastatic brain tumors and found that targeted therapy reduces cognitive decline and increases median survival rate by 218 days
The updated clinical guideline from the American Society for Radiation Oncology (ASTRO) underscores the safety and effectiveness of palliative radiation therapy (RT) for treating painful bone metastases. The guideline recommends optimal RT dosing schedules, including options for re-treatment, to provide pain relief, with a single 8-Gy ...
A QUT-led project has identified the mechanism by which melanoma cells switch from proliferative to invasive behavior, opening up new pathways for cancer treatment. The discovery reveals a specific regulatory pathway involving the NFIB-EZH2 axis, which could potentially be targeted with existing drugs.
A new technique separates circulating tumor cells from whole blood at a liquid-liquid interface, capturing 95% of CTCs in one minute. This method enables early detection and monitoring of metastatic disease, improving cancer treatment outcomes.
Researchers developed a new platform to switch MRI signals ON only in the presence of targeted diseases. The Nano MRI Lamp uses Magnetic Resonance Tuning (MRET) to control signal strength based on distance between magnetic materials.
A new gallium-68 labeled peptide BBN-RGD agent has been developed to target both gastrin-releasing peptide receptor and integrin αvβ3, providing dual-receptor targeting and advantages over single-receptor targeting. The agent has shown safety and effectiveness in detecting primary and metastatic prostate cancer lesions.
A study by the NRG Oncology Radiation Therapy Oncology Group found that adding antiandrogen therapy to radiation therapy can reduce the incidence of metastasis, death from prostate cancer, and overall deaths in patients with recurrent prostate cancer. The study showed a significant improvement in survival rates for patients treated wit...
A large study found that breast conserving therapy (BCT) is superior to mastectomy in early-stage breast cancer patients with no metastases. BCT, combined with radiation therapy, offers a survival advantage for patients aged over 50 years and those with comorbidity.
Researchers at the University of Illinois used a novel imaging technique to visualize microscopic shifts in metabolism and vesicle production in tumor cells. The study found that these changes can precede larger-scale events in the tumor environment, potentially preparing the way for cancerous cells to spread and metastasize.
Researchers at the University of Adelaide have identified a new microRNA that promotes cancer metastasis, leading to the development of a potential blood test for early detection. The discovery also reveals new targets for drugs that may inhibit cancer spread.
Researchers at the University of Missouri have discovered that luteolin, a natural compound found in herbs and vegetables, can inhibit the growth of triple-negative breast cancer cells in mice. The study found that luteolin reduced metastasis risk by preventing cancer cell migration and viability.
A Vanderbilt-led study identifies a compound that can reverse the malignant reprogramming of metastatic pancreatic cancer cells. The research found that distant metastases undergo massive epigenetic changes that enable tumor formation, but these changes can be reversed with the inhibition of phosphogluconate dehydrogenase enzyme.
Massachusetts General Hospital investigators identified a protein called G3BP2 that helps maintain aggressive tumor-initiating cells in breast cancer. Compounds like C108 can reduce the survival of these cells and slow tumor growth.
A study found that epigenetic changes, not DNA mutations, drive metastasis in pancreatic cancer cells. Researchers also identified a potential therapeutic target to block tumor formation in lab-grown cancer cells.
Scientists have designed an antibody-based therapy targeting the functions of TGF-beta that cause cancer. The therapy showed promise by slowing down breast cancer tumor growth and metastasis when GARP was deleted from mice with mammary tumors.
Researchers at Mayo Clinic have identified a key drug target, CDK4/6, which regulates the spread of triple-negative breast cancer. The study found that inhibiting this protein with CDK 4/6 inhibitors can prevent the metastasis of triple-negative breast cancer to distant organs.
Legumain (LGMN) is a cysteine protease over-expressed in tumor microenvironment, facilitating tumour growth and metastasis. Targeting LGMN directly or as a prodrug activator may offer promising cancer management strategies.
A study published in Nature discovered that fat utilization is required for the development and growth of lymphatic vessels, a key route for cancer cell spread. Researchers found that inhibiting fat usage can control lymphatic vessel growth, offering new avenues for preventing metastasis and treating complications like lymphedema.
The new Special Issue addresses topics in epidemiology, basic science, and policy, providing reliable information on digestive cancers in Latin America. Key findings include the rising incidence of gastric cancer and the need for awareness, with five articles from experts in the region.
Epigenetic changes in melanoma cells have been identified as key drivers of cancer metastasis. The study, published in Oncotarget, found that these changes can be reversed, making them a potential target for new therapies.
Scientists at The Wistar Institute have identified a novel protein pathway in mitochondria that controls energy production for cell invasion and metastasis across multiple cancer types. This pathway, previously observed in neurons, has strong clinical implications and represents a potential therapeutic target for several types of cancer.
WPI researchers develop a liquid biopsy chip that can trap and identify metastatic cancer cells in small amounts of blood. The device uses antibodies attached to carbon nanotubes, which create an electrical signature that can be detected to identify captured cells.
A team of investigators found that breast cancer cells with a few defined molecular alterations can spread to organs and form aggressive metastasis without a primary tumor. Most early spread cells remain dormant until a growth switch is activated.
Scientists discovered truncated p53 proteins that can promote cancer growth and metastasis. The mutant proteins interact with mitochondria and alter its functions, leading to tumor progression and poor outcomes.
Researchers at Uppsala University have developed a new method of antibody-based immunotherapy that targets tumor cells with minimal impact on other parts of the body. This alternative strategy has shown promising results in stimulating immune cells to attack and destroy cancer cells, potentially reducing adverse events.
Rates of breast cancer brain metastasis have not substantially declined despite improved targeted treatments for HER2-positive metastatic breast cancer. Researchers found that the risk of death from brain metastasis is more than twice that of patients with metastasis to other areas of the body.
Researchers at IRB Barcelona identify CD36 as a general marker of metastatic cells, which are responsible for initiating and promoting metastasis in several types of human tumors. High-fat diets have been shown to enhance the formation of metastases in mice inoculated with oral cancer cells.
Researchers at the University of Pittsburgh Cancer Institute have discovered molecular changes in primary tumors of breast cancer patients who developed brain metastases. The findings suggest that targeted therapies should be tailored not only for the original breast cancer but also for the brain tumors.
Research papers in PLOS Medicine discuss progress in cancer genomics, including whole-genome sequencing and gene expression changes. Studies on breast cancer and brain tumors provide insights into tumor evolution and metastasis, potentially leading to new treatments and prognosis estimation.
Researchers from IASLC present significant findings on osimertinib reducing disease progression by 70% in patients with non-small cell lung cancer. Additionally, studies demonstrate improved progression-free survival and reduced side effects for icotinib-treated patients with brain metastases.
Researchers at NUS have found that controlling TIP60 protein levels could prevent breast cancer cell spread. TIP60 interacts with DNMT1 and SNAIL2 to inhibit metastasis, suggesting a potential new strategy for treating various cancers.
Researchers at the University of Texas MD Anderson Cancer Center have discovered a link between the Golgi apparatus and lung cancer metastasis. The study found that targeting certain proteins in the Golgi can prevent tumor cells from spreading, offering a new potential therapeutic approach for preventing metastasis.
A new index called Lung-moIGPA has been developed to estimate survival in patients with non-small cell lung cancer and brain metastases. The updated Lung-moIGPA incorporates genetic and molecular data, including EGFR and ALK gene mutations, and predicts an overall median survival of 12 months.
A new study has identified BRD4 protein as a crucial driver of breast cancer cell dissemination, offering a promising new target for therapy. The findings may provide hope for patients with triple-negative breast cancer, the most aggressive and difficult-to-treat subtype.
Lung cancer is expected to result in an estimated 158,080 deaths in 2016 due to limited treatment options. Researchers are exploring signals within lung cancer cells that cause them to grow quickly and spread to other organs like the liver.
Researchers at Georgetown University Medical Center have developed a method to study cancer cell invasion and metastasis in real-time using zebrafish embryos. This approach allows for faster analysis of cancer questions, potentially leading to new treatments.
A team of scientists at the University of Alberta has discovered a protein marker, PDGFRA, that can help diagnose and treat aggressive papillary thyroid cancer. This finding could lead to more targeted treatments and reduce the need for unnecessary surgeries.
Researchers discovered that neutrophils, common white blood cells, can be hijacked by cancer cells to promote metastasis. A potential treatment using DNAse, an enzyme that degrades NETs, has shown promise in mice models of triple-negative breast cancer.
Researchers at the Research Institute of McGill University Health Centre (RI-MUHC) have discovered that some cancer cells can draw blood from existing mature blood vessels, allowing them to continue spreading. This breakthrough could lead to more personalized treatment options and improve the lives of patients with colon cancer.
PharmaMar's Phase 2 study shows significant reduction in tumor size and improved survival rates for patients with BRCA 1/2 metastatic breast cancer. The trial achieved an overall response rate of 41% with a 61% response rate in the BRCA 2 subgroup.
Tumor cells attract macrophages by releasing cytokines, which secrete growth factors that help tumor cells form spheroids and grow. Inhibiting these growth factors reduces tumor cell proliferation in a mouse model of ovarian cancer. This study sheds light on the early stages of ovarian tumor metastasis.
Cabozantinib significantly improves progression-free survival and response rate in patients with intermediate or poor-risk clear-cell metastatic renal cell carcinoma compared to sunitinib. The study also found a higher objective response rate in the cabozantinib arm.
Two phase II trials, KEYNOTE-052 and CheckMate 275, demonstrate the efficacy of PD-1 blockade with pembrolizumab and nivolumab in treating metastatic bladder cancer. The trials show a median survival benefit for patients with high PD-L1 expression.
Scientists from TUM discovered that pancreatic cancer cells create a 'niche' in the liver to grow and spread at an exceptionally early stage. This is facilitated by the protein TIMP1, which interacts with hepatic stellate cells to activate them and initiate metastasis.
Researchers harness microRNA therapy to block movement of cancer cells from primary tumors, preventing fatal proliferation and metastasis. The study's results suggest a promising approach for human breast cancer treatment.
Researchers at Sylvester Comprehensive Cancer Center have identified a receptor that slows breast cancer metastasis when targeted. By blocking the receptor for advanced glycation end-products (RAGE), scientists decreased tumor growth, reduced angiogenesis and inflammation, resulting in lower metastatic rates to the lung and liver.